{"id":"W3203989804","doi":"10.1016/j.annonc.2021.08.056","title":"660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"EMD Serono; Genentech; Aptitude Health; Ipsen; PharmaMar; European Society for Medical Oncology; Cilag; Astellas Pharma; Eisai; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer; Invitae; Chugai Pharmaceutical; EUSA Pharma; Society for Immunotherapy of Cancer","keywords":"Medicine; Internal medicine; Toxicity; Renal cell carcinoma; Oncology; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004982258,0.0008076063,0.003205885,0.0006340448,0.0002721731,0.001977571,0.001037285,0.0007152996,0.002297772],"category_scores_gemma":[0.0050017,0.0003318125,0.002848318,0.001547519,0.0002961764,0.001076183,0.0007344955,0.002959579,0.0007135644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001491617,"about_ca_system_score_gemma":0.001921416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002172213,"about_ca_topic_score_gemma":0.008119388,"domain_scores_codex":[0.9989807,0.0004407717,0.0001097356,0.0001052265,0.0002745005,0.00008909197],"domain_scores_gemma":[0.9965718,0.00149421,0.0009153201,0.0001532765,0.0005669163,0.0002984654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04074871,0.0009967266,0.0192381,0.007803282,0.008137281,0.0001151566,0.0002237879,0.005059725,0.003126802,0.001940403,0.1014666,0.8111435],"study_design_scores_gemma":[0.09440924,0.05273098,0.1664478,0.008545823,0.03722649,0.001618816,0.0004562706,0.005826553,0.003992856,0.01138126,0.6170002,0.0003637132],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.3166574,0.5564143,0.008695796,0.02611086,0.003450087,0.002164638,0.0425319,0.001037707,0.04293736],"genre_scores_gemma":[0.5625166,0.2958643,0.01600441,0.03092556,0.004111957,0.003715849,0.07099495,0.0008755443,0.01499084],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004982258,"threshold_uncertainty_score":0.02634907,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06371294213044976,"score_gpt":0.3759448895995288,"score_spread":0.312231947469079,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}